PROTOCOL TITLE 
Clinic al Performance Evaluation of the Bio-Self ‚Ñ¢ COVID-[ADDRESS_615193] NUMBER
[STUDY_ID_REMOVED]
VERSION NUMBER 
2.[ADDRESS_615194] of Abbreviations   
 
Term  Definition  
AE Adverse Event  
AN Anterior Nares  
CDC  Centers for Disease Control and Prevention  
CI Confidence Interval  
CFR  Code of Federal Regulations  
CLIA  Clinical Laboratory Improvement Amendments  
¬∞C Degrees Celsius  
CRF  Case Report Form  
CRO  Contract Research Organization  
Ct Cycle Threshold  
EUA  Emergency Use Authorization  
FDA  U.S. Food and Drug Administration  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practices  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
IFU Instructions for Use  
IRB Institutional Review Board  
IVD In Vitro Diagnostic  
LIVD  Laboratory In Vitro Diagnostics  
LOINC  Logical Observation Identifiers Names and 
Codes  
NPA Negative P ercent Agreement  
NSR  Non-Significant Risk  
PCR  Polymerase Chain Reaction  
PI [INVESTIGATOR_479302] P ercent Agreement  
QRI Quick Reference Instructions  
RT-PCR  Reverse Transcription Polymerase Chain Reaction  
SARS -CoV -[ADDRESS_615195] Information  
 
Sponsor:  
Sponsor Address:  
 
 
Sponsor Contact:  
[CONTACT_479311]:  
Sponsor E -mail: BioTeke [LOCATION_003], LLC.  
[ADDRESS_615196].  
Suite 2304  
Miami, F L [ZIP_CODE]  
Chang Oh Turkmani  
[PHONE_10026]  
sales@bioteke -[LOCATION_003].com  
CRO:  
CRO Address:  
CRO Contact:  
[CONTACT_479312]:  
CRO E -mail:  CSSi L ifeSciences  
[ADDRESS_615197] Linthicum Heights, MD [ZIP_CODE]  
Janice C attano  
[PHONE_10027]  
[EMAIL_9233]  
 
2.2. Site Investigator Contact  
 
A list of the names and titles of clinical investigators and the addresses and telephone numbers of study 
sites will be maintained in the sponsor master files.  
 
  
  
BioTeke_Home Use_Clinical Performance Study_V2.0_5 May 2022.docx  Page 6 of 26 3. Protocol Approval Page  
Study Title:  Clinical Performance Evaluation of the Bio-Self‚Ñ¢ COVID -[ADDRESS_615198]  
Protocol Number  BTK -01-1002  
Version  2.0 
Date of Issue  05 May  2022  
Sponsor Name [CONTACT_13311] : BioTeke [LOCATION_003], LLC.  
[ADDRESS_615199] read and approve this protocol and agree on its content.  It is confirmed that the information 
and guidance given in this protocol complies with scientific principles.  
 Name [CONTACT_479324]:  [CONTACT_479313] : President   
  
  
BioTeke_Home Use_Clinical Performance Study_V2.0_5 May 2022.docx  Page 7 of 26  
4. Investigator Protocol Agreement  
Protocol Title:  Clinical Performance Evaluation of the Bio-Self‚Ñ¢ COVID -[ADDRESS_615200]  
Protocol Number : BTK -01-1002  
Version : 2.[ADDRESS_615201] (IRB) review and approval in [ADDRESS_615202] igator‚Äôs Signature        [CONTACT_1782]  
 
 
 
____________________________________________________  
Print Name   
  
[CONTACT_479325]_Home Use_Clinical Performance Study_V2.0_5 May 2022.docx  Page [ADDRESS_615203].  The study will evaluate the accuracy 
(sensitivity and specificity) in a simulated home use environment of the Bio-
Self COVID -[ADDRESS_615204] when compared to the PerkinElmer New 
Coronavirus Nucleic Acid detection kit , a high -sensitivity Emergency Use 
Authorization (EUA) SARS -CoV -2 RT -PCR assay.  
   
Investigational 
Material/Product  The Bio-Self COVID -[ADDRESS_615205]  when compared to a high -sensitivity 
Emergency Use Authorization (EUA) SARS -CoV -[ADDRESS_615206]  by [CONTACT_479314] 
a high  sensitivity EUA SARS -CoV -2 RT -PCR assay to calculate both the 
positive percent agreement  [(PPA) sensitivity] and negative percent agreement  
[(NPA) specificity ].  
 
The order of testing will be 1) standard of care (SOC) collection by a healthcare 
practition er, 2) layperson conducts the test on themselves or another study 
participant using the Bio -Self Test , and 3) comparator test collection by [CONTACT_479315].  
 
Inclusion Criteria  Subjects are eligible for inclusion only if all of the following criteria are met:  
1. An Institutional Review Board (IRB) approved informed consent  and 
assent , if applicable,  is signed and dated prior to any study -related 
activities.  
2. Male and female Subjects [ADDRESS_615207] is willing to provide a self -collected nasal swab sample.  (If under 
the age of 14, the sample will be collected by [CONTACT_107119].)  
4. Subject is willing to have a nasal swab collected by a healthcare 
professional.  
5. Subject agrees to complete all aspects of the study.  
 
Exclusion Criteria  A Subject is not eligible for inclusion if any of the following criteria apply:  
  
BioTeke_Home Use_Clinical Performance Study_V2.0_5 May 2022.docx  Page [ADDRESS_615208] three (3) months.  
4. Subject  uses home diagnostics, e.g., HIV Tests , glucose meters , etc.  
 
Target Population/ 
Sample Size  The first 50 subjects will be consecutively enrolled (i.e., in an ‚Äúall comers‚Äù 
style) including those who are either asymptomatic or symptomatic  for COVID -
19. Following the enrollment of  the first [ADDRESS_615209] include : 
‚Ä¢ At least 10 RT -PCR confirmed positive specimens  collected from 
subjects  that are asymptomatic for COVID -19. 
‚Ä¢ At least 30 RT -PCR confirmed positive specimens collected from 
subjects that are symptomatic for COVID -19. 
‚Ä¢ At least 30 children between 2 ‚Äì 13 years of age.  
‚Ä¢ Representation in the following age groups:  
‚Ä¢ <14 years of age, where the Parent or legal guardian collects a 
sample from their child (e.g., age s 2-13) and performs the test .  
‚Ä¢ 14-24 years of age  
‚Ä¢ 25-64 years of age  
‚Ä¢ ‚â•65 years of age  
‚Ä¢ At least 10 -20% of the clinical samples are low positive.  
Current estimates of positive cases are approximately  8 % of all -comers. Up to 
[ADDRESS_615210] 10-20% being low positive .  
Site Requirements  Up to three (3) sites , with a minimum of [ADDRESS_615211] with lay users ‚Äô self-collection and testing or adult  
collection and testing for those ages [ADDRESS_615212] results. Accuracy will refer to positive 
percent agreement [(PPA) sensitivity] and negative percent agreement 
[(NPA) specifi city].  
 
 
  
  
BioTeke_Home Use_Clinical Performance Study_V2.0_5 May 2022.docx  Page 10 of 26 6. Introduction  
6.1. Background  
6.1.1.  COVID -19 is a contagious respi[INVESTIGATOR_4375], caused by [CONTACT_479316], 
Severe Acute Respi[INVESTIGATOR_7531] 2 (SARS -CoV -2). This is a communicable 
disease easily transmitted through aerosolized droplets containing the infectious virus. Infections 
with SARS -CoV -[ADDRESS_615213]  when compared to a high -sensitivity Emergency Use Authorization (EUA) 
SARS -CoV -2 RT -PCR assay . 
6.3. Risk and Benefit Assessment  
6.3.1.  Potential Risks  
[IP_ADDRESS]  The only study -related procedures that could impact Subject safety is in the collection of 
nasal swabs.  The risks of collecting a nasal swab may include sympt oms associated with 
standard collection practices such as slight pain and/or a small amount of bleeding in the 
nose.   
[IP_ADDRESS]  Subject(s) will be de -identified using a study -specific number at the time of enrollment.  All 
study forms, Case Report Forms ( CRFs) and study samples will be labeled with the de -
identified s ubject  ID number. No identifiable patient information will be provided to 
BioTeke [LOCATION_003], LLC .  No patient treatment or management decisions will be based on any 
results generated from the investig ational kit during this study.  
[IP_ADDRESS]  Information collected for this study is confidential. However, officials of FDA or other 
regulatory agencies may research records during the ordinary course of carrying out their 
functions.  A sponsor representative m ay also inspect research records to make certain the 
study data is accurate.  The Investigator, institution, regulatory agencies and sponsor will 
protect the confidentiality of the records.  
6.3.2.  Potential Benefits  
[IP_ADDRESS]  The information obtained in this study will not benefit the study subjects directly but  may 
aid future patients by [CONTACT_4205][INVESTIGATOR_479303] -
CoV -2. 
6.4. Study Device Description  
The Bio-Self COVID -[ADDRESS_615214] antigen of the 
SARS -CoV -2 from the  anterior nares (Nasal) specimens from patients with or without symptoms or other 
epi[INVESTIGATOR_479304] a COVID -[ADDRESS_615215] along the nitrocellulose membrane until 
captured by [CONTACT_094] -coated monoclonal antibodies of SARS -CoV -2 in the detection zone on the nitrocellulose f ilm 
(Test line ‚Äì T) to form a pi[INVESTIGATOR_8745]/purple reaction line  on the detection zone, indicating the result is positive.  
Conversely, if there is no viral antigen or the concentration of antigen in the  specimen is below the minimum 
detection limit, no pi[INVESTIGATOR_8745]/purple  reaction line appears in the detection zone and the result is considered negative.   
Regardless of whether or not  the sample contains viral antigens, the pi[INVESTIGATOR_8745]/purple reaction line that appears in 
the quality control zone (Control line ‚Äì C) is the criterion  for determining if the chromatography process is 
performing properly.    
6.4.2.  Device Output  
Bio-Self COVID -[ADDRESS_615216] line (T) and control line (C) indicate a positive result.  
2. A single control line (C) indicates a negative result.  
3. A test line (T) only , or the absence of the control line (C)  and test line (T) , or blurred  lines 
indicate an invalid test.  
 
Positve Result  
 
 
  
 
 
 
 
C-Line  T-Line  Result  
Pi[INVESTIGATOR_8745]/purple  Pi[INVESTIGATOR_8745]/purple  Positive  
  
BioTeke_Home Use_Clinical Performance Study_V2.0_5 May 2022.docx  Page 12 of 26 Negative Result  
 
 
 
 
        
 
 
 
Invalid Result  
 
 
 
 
                        
 
C-Line  T-Line  Result  
Pi[INVESTIGATOR_8745]/purple  Colorless  Negative  
C-Line  T-Line  Result  
Colorless  Colorless  or pi[INVESTIGATOR_8745]/purple  Invalid, retest  
  
BioTeke_Home Use_Clinical Performance Study_V2.0_5 May 2022.docx  Page [ADDRESS_615217] anterior 
nasal (nares) swab samples from individuals aged 1 4 years or older or adult collected anterior nasal 
swab samples from individuals aged 2 ‚Äì [ADDRESS_615218] should self - isolate and seek follow -up care with their physician or healthcare provider as 
additional testing may be necessary.  
Negative resul ts should be treated as presumptive and confirmation with a molecular assay for 
patient management, may be performed if necessary.  Negative results do not rule out SARS -CoV -2 
infection and  should not be used as the sole basis for treatment or patient mana gement decisions, 
including infection control decisions. Negative results should be considered in the context of an 
individual‚Äôs recent exposures, history, and the presence of clinical signs and symptoms consistent 
with COVID -19. Additional confirmatory te sting with a molecular test for positive results may also 
be necessary, if there is a low likelihood of COVID -19, such as in individuals without known 
exposures to COVID -[ADDRESS_615219] n egative and continue to experience COVID -like symptoms of fever, cough and/or 
shortness of breath may still have SARS -CoV -[ADDRESS_615220] to relevant public health authorities in 
accordance with local, state, and f ederal requirements using appropriate LOINC and SNOMED 
codes, as defined by [CONTACT_206090] (LIVD) Test Code Mappi[INVESTIGATOR_206075] -
CoV -[ADDRESS_615221] anterior nares (nasal) specimens directly collected from subjects 
suspected of COVID -[ADDRESS_615222]   
used in this study will not be used for diagnostic purposes or patient management.  
6.5.2.  Results are for the identification of SARS -CoV -2 nucleocapsid antigen. Antigen is generally 
detectable in nas al samples during the acute phase of infection. Positive results indicate the 
presence of viral antigens, but clinical correlation with patient histor y and other diagnostic 
information is necessary to determine infection status. Positive results do not rule out bacterial 
infection or co -infection with other viruses. The agent detected may not be the definite cause of 
disease.  
6.6. Study Sites  
6.6.1.  Study enrollmen t for this study will be conducted at up to three  (3) clinical  sites with at least two 
testing locations . The testing locations have a  diverse demographic patient population with 
varying educational backgrounds.   
 
  
BioTeke_Home Use_Clinical Performance Study_V2.0_5 May 2022.docx  Page [ADDRESS_615223] will be conduc ted at a minimum of one (1) CLIA certified 
laboratory within the U.S.  
6.6.3.  The applicable IRB/EC will review and approve the study protocol, informed consent and assent 
documents , Quick  Reference  Instructions  (QRI) and any other patient facing materials  prior t o 
enrolling Subjects into this study.  
6.7. Study Objectives  
6.7.1.  The primary objective of this study is to determine the accuracy  (in terms of sensitivity and 
specificity)  of the Bio-Self COVID -[ADDRESS_615224]  when compared  to the PerkinElmer 
New Coronavirus Nucleic Acid detection kit , a high -sensitivity Emergency Use Authorization 
(EUA) SARS -CoV -[ADDRESS_615225] on themselves or on another study participant.  Potential subjects will 
be those  presenting for COVID -19 testing.   
Subjects that present for COVID -19 testing (both symptomatic and asymptomatic) that meet the eligi bility criteria 
will be enrolled in to this study. The subject  population may include English and Spanish speaking  individuals across 
all ages 2 ‚Äì 65+ years . The following age groups must be represented : 
‚Ä¢ <14 years of age, where the Parent or legal guardian collects a sample from their child (e.g., age 2 -13) and 
performs the test  
‚Ä¢ 14-24 years of age  
‚Ä¢ 25-64 years of age  
‚Ä¢ ‚â•[ADDRESS_615226] of care (SOC)  test performed by a healthcare practitioner.  To mitigate any 
potential bias which may affect the subject‚Äôs  visual interpretation  of the Bio-Self COVID -[ADDRESS_615227] self -collection  (or adult tester)  the healthcare practitioner  will 
collect the  nasal sample for the RT -PCR comparator.  
 
Comparator:  
The subjects will have a healthcare practitioner collect two nasal sample s, one for the  SOC testing  and the second for 
the comparator test .  The SOC  sample will be used for patient management . Again, the results of the SOC will not be 
shared with the subje ct until the subject has interpreted the results from the Bio -Self COVID -[ADDRESS_615228] should be instructed to 
blow their nose prior to each sample collection.    The comparator sample will be tested at a CLIA lab  using the  
PerkinElmer New Coronavirus Nucleic Acid detection kit . Positive sample s (RT-PCR and Bio -Self COVID -[ADDRESS_615229])  will be sequenced by [CONTACT_479317] . Once  [ADDRESS_615230] been identified , no further sequencing will be performed.   Additionally, to en sure 10 -20% of the 
samples are low positive, a  cycle threshold  (Ct) count will be performed for all RT -PCR positive samples.  Low 
positives are defined as samples in which any gene target is within [ADDRESS_615231]‚Äôs of the mean Ct count of the RT-PCR 
comparator  test‚Äôs LoD . The following information will be collected and provided in the EUA application.  
 
‚Ä¢ specimen collection device  
‚Ä¢ specimen volume,  
‚Ä¢ eluate volume,  
  
BioTeke_Home Use_Clinical Performance Study_V2.0_5 May 2022.docx  Page 15 of 26 ‚Ä¢ specific extraction kit,  
‚Ä¢ extraction equipment,  
‚Ä¢ consumables  
‚Ä¢ platform.  
 
Line data collection:  
The original information and data for each subject will be collected in an exc el spreadsheet including the 
following data elements for each specimen tested:  
 
‚Ä¢ Specimen type for the antigen test  
‚Ä¢ Specimen collection date and time for the antigen test  
‚Ä¢ Specimen testing date and time for the antigen test  
‚Ä¢ VTM type, as applicable, for the PCR  
‚Ä¢ Antigen test result with the reader  
‚Ä¢ Specimen type for RT -PCR  
‚Ä¢ Specimen collection date and time for RT -PCR test  
‚Ä¢ Specimen testing date and time for RT -PCR test  
‚Ä¢ Name [CONTACT_479326] -PCR used as the comparator for each specimen  
‚Ä¢ RT-PCR test resul ts (+/ -) 
‚Ä¢ RT-PCR test value results (Ct values)  for positive samples  
‚Ä¢ RT-PCR and Bio-Self COVID -[ADDRESS_615232] 30 samples . 
‚Ä¢ Indicate if subject is a symptomatic or symptomatic.  If symp tomatic which of the following symptoms are 
they experiencing: Fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body 
aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, other -specify.  
‚Ä¢ Number of days post -onset of patient symptoms  
‚Ä¢ Subject  age, sex, race and ethnicity,  if available.  
 
7. Study Enrollment and Withdrawal  
7.1. Study Population  
7.1.1.  Enrollment population should represent different socioeconomic and educational backgrounds.  
7.1.2.  High risk indivi duals should not be excluded from the study . 
7.1.3.  Both symptomatic and asymptomatic individual s should be enrolled in the study . 
7.1.4.  At least thirty ( 30) children ages of 2 ‚Äì [ADDRESS_615233] include subjects in the following age groups:  
‚Ä¢ <14 years of age, where the Parent or legal guardian collects a sample from their 
child (e.g., age s 2-13) and performs the test  
‚Ä¢ 14-24 years of age  
‚Ä¢ 25-64 years of age  
‚Ä¢ ‚â•[ADDRESS_615234] 50 s ubjects should be consecutively enrolled (i.e., in ‚Äúall comers‚Äù style) , including those 
who are either asymptomatic or symptomatic for COVID -19.  Following the enrollment of the 
first [ADDRESS_615235] that presents for COVID -19 testing (both 
symptomatic and asymptomatic) that meets the eligibility criteria.  
7.2. Subject I nclusion Criteria  
To be enrolled in the study, the subject must meet all of the following inclusion criteria : 
1. An Institutional Review Board (IRB) approved informed consent  and assent , if applicable , is 
signed and dated prior to any study -related activities . 
2. Male and female Subjects [ADDRESS_615236] is willing to provide a self -collected nasal swab sample.  (If under the age of 14, the 
sample will be collected by [CONTACT_107119].)  
4. Subject is will ing to have nasal swab s collected by a healthcare p rofessional . 
5. Subject agrees to complete all aspects of the study.  
 
7.3. Subject Exclusion Criteria  
To be enrolled in the study, the subject must not meet any of the following exclusion criteria:  
1. Subject has a visual impairment that cannot be restored with glasses or contact [CONTACT_13276].  
2. Subject has prior medical or laboratory training.   
3. Subject had positive COVID -[ADDRESS_615237]‚Äôs involvement in the study will last for approximately one (1) hour.  No follow -up or 
subsequent subject involvement is required.  
7.5. Subject Withdrawal  
7.5.1.  Subjects may discontinue their participation in the study at any time.  A subject may be withdrawn 
from the study at any time at the discretion of the Investigator.  
7.6. Reason for Withdrawal  
A subject may be considered withdrawn for the purpose of this study if:  
‚Ä¢ Subject or parent of subject withdraws consent for study participation  
‚Ä¢ Subject non -compliance  
‚Ä¢ Investigator decision to withdraw subject as study participation is no longer in the 
subject‚Äôs best interest   
8. Study Procedures  
8.1. Screening  
8.1.1.  Informed consent  
[IP_ADDRESS]  Study staff will be notified upon presentation of eligible subjects to the clinical site.  Study 
staff trained in basic human research subject‚Äôs protection will explain the study protocol, 
procedures and objectives to the patient and obtain written informe d consent and assent (if 
applicable) for participation in the study from each subject prior to performing any study 
procedures in accordance with requirements outlined in the Code of Federal Regulations 
(CFR) Title 45, Part 46 and Title 21, Part 50.  This will be done by [CONTACT_479318] /Assent form (if applicable), allowing the subject ample time 
  
BioTeke_Home Use_Clinical Performance Study_V2.0_5 May 2022.docx  Page 17 of 26 to review the form(s), ask questions and have their questions answered to the satisfaction of 
the Subject.  
[IP_ADDRESS]  Subjects  wishing to participate will be asked to sign the Consent/Assent form (if applicable) 
and will be provided with a copy for their records; the original will be maintained with the 
Subject‚Äôs study records.  The Consent/Assent Form will be presented to the el igible Subjects 
in a language that is fully comprehensible to the Subject.  
8.1.2.  Vulnerable Populations  
[IP_ADDRESS]  Studies will be conducted in accordance with the relevant articles of the Declaration of 
Helsinki.  The Declaration of Helsinki defines vulnerable ind ividuals as having ‚ÄúAn 
increased likelihood of being wronged or of incurring additional harm.‚Äù  For the purpose of 
this study,  we define vulnerable individuals as those whose capacity to protect or exercise 
their rights is restricted due to their mental, s ocial, economic or ethnical status, age or health 
condition.  Subjects deemed vulnerable by [CONTACT_4158]/or the Principal Investigator [INVESTIGATOR_479305].  
[IP_ADDRESS]  This study involves children who have not attained the legal age for consent to treatment or 
procedures involved in research and are a vulnerable population.  Children are a group 
already burdened by [CONTACT_4113] -[ADDRESS_615238] Eligibility  
[IP_ADDRESS]  Once written informed consent has been obtained from the subject, a  Case Report Form 
(CRF ) will be completed to document adherence to the inclusion and exclusion criteria.  
[IP_ADDRESS]  Where a subject fails to fulfill any element of the inclusion and exclusion criteria, this will 
be documented and the signed consent form and completed inclusion/exc lusion criteria 
retained by [CONTACT_079].  The subject will not be advanced any further into this 
clinical investigation.  
8.2. Study Enrollment  
8.2.1.  Subject Identification  
[IP_ADDRESS]  When a subject is considered eligible for entry into this clinical stud y, the subject will be 
allocated a study -specific number (Subject ID number).  This number will be a unique 
identifier to the subject and written on each page of the CRF, and all other documentation 
relating to that subject.  
[IP_ADDRESS]  The Subject ID number w ill consist of the study site testing location  number and a sequential 
enrollment number at that location . For example, the third subject enrolled at site [ADDRESS_615239] ID 01 -003. 
[IP_ADDRESS]  The Principal Investigator (PI) or designee at each site wi ll maintain a master log that will 
correlate each Subject ID number to the subject‚Äôs name.  This log will remain at the study 
site and will be confidential . 
8.2.2.  Subject Information  
[IP_ADDRESS]  The following information will be obtained and documented on the approp riate CRF for all 
subjects enrolled in the study:  
‚Ä¢ Age (age of the subject and of the person performing the test)  
‚Ä¢ Sex  
‚Ä¢ Race  
‚Ä¢ Ethnicity  
‚Ä¢ Level of education  (of the person performing the test)  
  
BioTeke_Home Use_Clinical Performance Study_V2.0_5 May 2022.docx  Page 18 of 26 ‚Ä¢ Occupation (of the person performing the test)  
‚Ä¢ Exposure to someone with COVID -[ADDRESS_615240] . 
‚Ä¢ Presence or absence of  one or more  COVID -19 symptoms, specifically: fever over 100¬∞ 
F or chills; cough; shortness of breath; difficulty breathing; muscle or body aches ; 
fatigue; sore throat; headache;  congestion or runny nose;  new loss of taste or smell.  
Subjects will be asked how many days prior to the test the symptoms appeared.  
‚Ä¢ COVID -[ADDRESS_615241] 
dose.   
8.3. Group Assignment  
8.3.1.  Subjects  will b e assigned to one of two groups: Self -Test or Pediatric Test .  
[IP_ADDRESS] The Self -Test group will include the subject  only. [IP_ADDRESS] The Pediatric group will 
include an adult tester and a pediatric subject (age 2 ‚Äì 13). 
8.3.2.  The healthcare practitioner will first collect the SOC sample.  To mitigate any potential bias which 
may affect the subject‚Äôs visual interpretation of the Bio-Self COVID -[ADDRESS_615242] (or adult tester ) will be provided with the Bio-Self COVID -[ADDRESS_615243]  
and the Quick Reference Instructions  (QRI) .  
8.3.5.  After a minimum o f [ADDRESS_615244]  (or adult tester) sample collection , the healthcare 
practitioner will collect the nasal sample from the subject ,  that will be used for  the Comparator.  
8.3.7.    A minimum of [ADDRESS_615245] will be aske d 
to blow their nose prior to collecting each sample.  
 
[IP_ADDRESS] The  comparator sample will be labeled with the subject‚Äôs study identification number.  
[IP_ADDRESS] The comparator sample will be shipped to the CLIA laboratory conducting the RT -PCR test . 
A Ct val ue will be obtained for all RT -PCR positive samples.   A minimum of [ADDRESS_615246] . Confirm a time and date for an 
unscheduled visit . 
8.4.3.  Follow the steps under Section 8.3.2. ‚Äì 8.3.5.  
9. Problem Reporting  
If problems occur during the conduct of the stud y, the clinical monitor should be notified within five (5) days of 
incident.  
10. Premature Study Termination or Suspension  
10.1. This study may be suspended or prematurely terminated by [CONTACT_479319]. Written notification via email or post, documenting the reason for study suspension or 
termination, will be provided by [CONTACT_101514]. If the study is prematurely terminated or 
  
BioTeke_Home Use_Clinical Performance Study_V2.0_5 May 2022.docx  Page 19 of 26 suspended, the Principal Investigator [INVESTIGATOR_33894](s) for 
suspension or termination.  
10.2. Circumstances tha t may warrant termination include, but are not limited to:  
‚Ä¢ Insufficient adherence to protocol requirements.  
‚Ä¢ Data that are not sufficiently complete and/or evaluable.  
‚Ä¢ Determination of futility  
11. Safety Considerations  
11.1. Safety Warnings and Precautions  
Handle all samples as potentially infectious according to universal precautions and good laboratory practices (GLP) .  
Use an appropriate disinfectant for decontamination. Store and dispose of these materials and their containers in 
accordance with local re gulations and guidelines.  
 
11.2. Definition of Adverse Events  
11.2.1.  An Adverse Events (AE) is any untoward medical event that occurs to the subject during the 
course of a study (with onset after the first study -specific procedure), whether or not that event is 
conside red study -related.  
11.2.2.  An adverse event may be mild, moderate or severe and are usually unexpected.  
11.2.3.  All adverse events observed by [CONTACT_079] [INVESTIGATOR_479306], must be 
reported to the Sponsor within [ADDRESS_615247] been produced by [CONTACT_206093]. For the purpose of this study, only the collection of nasal nares swab s is considered to 
be the study procedure s. 
11.3. Reporting of Serious Adverse Events  
11.3.1.  A Serious Adverse Event  (SAE) is any adverse event that:  
‚Ä¢ led to death  
‚Ä¢ led to a serious deterioration in the health of the subject that either resulted in a life -
threatening illness or injury, or a permanent impairment of a body structure or a body 
function, or in-patient hospi[INVESTIGATOR_869] , or in 
medical or surgical intervention to prevent life -threatening illness or injury or permanent 
impairment to a body structure or a body function  
‚Ä¢ led to foetal  distress, foetal  death or a congenital abnormality or birth defect  
11.3.2.  Hospi[INVESTIGATOR_206080] [ADDRESS_615248] be reported to the Sponsor by [CONTACT_16470] 24 hours of 
the Principal Investigator [INVESTIGATOR_206081].    
11.3.4.  The Sponsor will be contact[CONTACT_479320]:  
Contact [CONTACT_5627]:  Chang Oh Turkmani  
 
Telephone Number:   [PHONE_10026]  
 
11.3.5.  The Principal Investigator [INVESTIGATOR_206082] -up measures in 
accordance with good medical practice but should notify the monitor of such actions and 
record them in the Subject‚Äôs CRF .  Each telephone reported reaction must b e reported in 
writing to the monitor within [ADDRESS_615249] 
anterior nares  (nasal)  swab .  The risks of collecting a nasal nares swab may include symptoms 
associated with standard collection practices such as slight p ain, minor bleeding.  Subjects will 
be identified using a study specific number at the time of enrollment.  All study forms and any 
associated laboratory reports will be labeled with the subject  number.  No identifiable patient 
information will be provided  to the Sponsor . No patient treatment or management decisions will 
be based on any results generated from this study , with the exception of the Standard of Care 
sample . 
11.4.2.  Information collected for this study is confidential. However, officials of FDA or othe r 
regulatory agencies may research records during ordinary course of carrying out their functions. 
A sponsor representative may also inspect research records to make certain the study data is 
accurate.  The Investigator, institution, regulatory agencies an d Sponsor will protect the 
confidentiality of the records.  
11.4.3.  No medical decisions will be based on investigational assay results generated as part of the 
study.  
12. Regulatory and Administrative Requirements  
12.1. FDA Guidance on EUA  
FDA Guidance on EUA testing and data acknowledges these products are not subject to [ADDRESS_615250] protection regulations (45 CFR 46) apply.  This study does not meet the definition of a clinical 
investigation as defined by [ADDRESS_615251] to IRB surrogate determination of risk. This study is, 
however, a non-significant risk (NSR) study in that nasal sample collection is not considered invasive and the test 
results will not be used to manage clinical care. Implementa tion of this study will include waiver of otherwise -
applicable GCPs to accommodate the emergency response COVID -[ADDRESS_615252] of the study at their site(s).  The investigator will 
ensure that the study is conducted in compliance with GCP, the protocol, the Clinical Study Agreement, and 
applicable regulations in 45 CFR 46, and any other applicable regulatory req uirements.  These requirements include:  
‚Ä¢ Obtaining IRB approval for the study and related documents before study initiation and enrolling Subjects.  
‚Ä¢ Obtaining informed consent from each subject in accordance with 21 CFR Part 50, as applicable.  
‚Ä¢ Protecting th e rights, safety, and welfare of Subjects under their care.  
‚Ä¢ Reporting adverse events.  
‚Ä¢ Coordinating and providing reasonable medical care to subjects for an adverse event  related to study 
participation.  
‚Ä¢ Reporting protocol deviations to the sponsor and IRB p er IRB requirements.  
‚Ä¢ Maintaining traceability and secured storage of all test kits and study samples.  
‚Ä¢ Ensuring confidentiality of all study documents, procedures, and study samples.  
 
12.3. Responsibility of Sponsor  
12.3.1.  The sponsor has the overall responsibility for the conduct of the study, including assurance 
that the study meets the FDA EUA regulations and other regulatory requirements as applicable.   
The sponsor‚Äôs study -related duties and functions may be transferred  to a contract research organization 
(CRO).  
12.4. Protocol Deviations  
12.4.1.  A protocol deviation is failure to comply with the requirements specified within the clinical 
study protocol or IRB requirements. Investigators are not allowed to deviate from the protocol 
  
BioTeke_Home Use_Clinical Performance Study_V2.0_5 May 2022.docx  Page [ADDRESS_615253]‚Äôs rights and well -being, or the scientific 
integrity of the study.  
12.5. Changes to Protocol  
12.5.1.  In the event the study protocol is amended, the monitor  will provide the Principal 
Investigator [INVESTIGATOR_1246](s) and a revised protocol.  
 
12.5.2.  Protocol amendments that affect the Subject rights, safety, or welfare must be submitted to 
and approved by [CONTACT_1201]. The Investigator must be notified of the approval, in writing, prior to 
implementation.  
12.6. Reco nciliation of Study Material, Supplies and Samples  
The Sponsor will supply sufficient quantities of study materials and supplies to enable the site to complete the study 
and the site will return all unused materials and supplies to the Sponsor  or dispose o f according to provided 
instructions. The site is required to maintain the inventory of these materials provided and document the 
reconciliation of these materials. If materials are disposed at the study site, the Investigator must provide the Sponsor 
with a signed record of disposition.  
 
13. Statistical Considerations  
Except where otherwise specified, the following general principles apply to the planned statistical analyses. All 
statistical analysis will be conducted using a current version 9.4 (or later) of SAS (SAS Institute Inc., Cary, NC), 
Excel version 2010 or later, or other widely accepted  statistical or graphical software as required.   Continuous 
variables (e.g., age) will be summarized by [CONTACT_14458]; mean, standard deviation and median. Categorical  
variables (e.g., sex) will be summarized with frequency counts and percentages. Confidence intervals (CI) may be 
presented, where appropriate, using the exact method for categorical variables.  In general, percentages will be 
displayed to [ADDRESS_615254] include subjects in the following age groups:  
‚Ä¢ <14 years of age, where the Parent o r legal guardian collects a sample from their child (e.g., age 2 -13) 
and performs the test  
‚Ä¢ 14-24 years of age  
‚Ä¢ 25-64 years of age  
‚Ä¢ ‚â•65 years of age  
Current estimates of positive cases are approximately  8% of all -comer s.  Up to [ADDRESS_615255] EUA SARS -CoV -2 RT -PCR  Comparator 
Assay  
Pos Neg Total  
Pos ùëõ11 ùëõ12 ùëõ1. 
Neg ùëõ21 ùëõ22 ùëõ2. 
Total  ùëõ.1 ùëõ.2 ùëõ.. 
Pos=positive, Neg=negative.  
Based on the notation of Table 1, The sensitivity, specificity and 95% two -sided exact binomial confidence interval 
will be established.  
The sensitivity is computed as the proportion of positive samples as called by [CONTACT_479321] -CoV -[ADDRESS_615256] ; the sensitivity shall be computed as 
the ratio of ùëõ11 / (ùëõ11 + ùëõ21).   
The specificity is computed as the proportion of negative samples as called by [CONTACT_479321] -CoV -[ADDRESS_615257] ; the specificity shall be 
computed as the ratio of ùëõ22 / (ùëõ12 + ùëõ22 ). 
13.2.2.  Performance Study - Percent Agreement  
A [ADDRESS_615258] results, based on the positive and negative outcomes.  
Based on the notation of Table 1, T he percent agreement and 95% two -sided exact binomial confidence interval will 
be established.  
The overall percent agreement shall be computed as equal to 100% x ( n11 + n 22)/(n11 + n 12 + n 21 + n 22) 
The positive percent agreement (PPA) shall be computed as  equal to 100% x n11/( n 11 + n 21) 
 
The negative percent agreement (NPA) shall be computed as equal to 100% x n22/( n 12 + n 22) 
 
Per FDA ‚Äôs Template for Developers of Molecular and Antigen  Diagnostic COVID -[ADDRESS_615259] for Home Use  dated 
11/09/2021 , the following performance criteria will be used:  
‚Ä¢ NPA ‚â•98%  
‚Ä¢ PPA  
‚ñ™ For OTC single -use testing in all patient populations, including individuals with or without 
symptoms or other epi[INVESTIGATOR_479307] -19: ‚â• 80% PPA demonstrated 
in a clinical evaluation including both symptomatic and asymptomatic individuals;  
‚ñ™ For OTC testing in all patient populations, including individuals with or without symptoms 
or other epi[INVESTIGATOR_479308] -19, with additional mitigations such as 
serial screening, as discussed in the ‚ÄúSupplemental Template for Developers of Molecular 
and Antigen Diagnostic COVID -19 Tests for Screening with Serial Testing‚Äù1: ‚â• 80% PPA 
with a lower bound (LB) of th e two sided 95% confidence interval (CI) ‚â•70%, demonstrated 
 
1 Available at https://www.fda.gov/media/146695/download . 
  
BioTeke_Home Use_Clinical Performance Study_V2.0_5 May 2022.docx  Page 23 of 26 in a clinical evaluation including symptomatic individuals only or both symptomatic and 
asymptomatic individuals;  
‚ñ™ For prescription home use single -use testing in individuals suspected of COVID -19 by [CONTACT_479322]: ‚â• 80% PPA demonstrated in a clinical evaluation including 
symptomatic individuals only (note that, for antigen tests, the indication may be limited to 
symptomatic individuals within a certain number of days of symptom onset, depending on 
the data); or  
‚ñ™ For OTC single use  testing in symptomatic individuals: ‚â•80% PPA demonstrated in a 
clinical evaluation including symptomatic individuals only (note that, for antigen tests, the 
indication may be limited to symptomatic individuals within a certain number of days of 
symptom onset, depending on the data).  
14. Ethical Considerations  
The investigator and site study staff will be responsible for the ethical conduct of this study in accordance with [ADDRESS_615260] (IRB) responsible for the 
studies to be conducted at each site or a central IRB must provide written approval of the protocol 
and informed  consent. The investigator will provide IRB documentation for all applicable IRB 
submissions to the Sponsor. If IRB approval is withdrawn, the investigator will immediately 
report this to the Sponsor.  
14.2. Informed Consent Process  
14.2.1.  Informed consent is a process that is initiated prior to the Subject‚Äôs agreement to participate 
in the study and continues throughout the study participation.  The Principal Investigator [INVESTIGATOR_479309], including any risks and benefits, it s purpose 
and procedures, and expected duration of involvement in the clinical study.  Each patient must be 
informed that participation in the clinical study is voluntary and non -participation will not affect 
his / her right to the most appropriate treatme nts or affect the doctor/clinician -patient relationship.  
Each patient must be given sufficient time to decide whether they wish to participate and have all 
their queries addressed prior to signing the IRB -approved consent form(s).  A copy of the signed 
consent form(s) must be provided to the patient.  Study specific procedures will not be initiated 
until the Subject has signed and dated the appropriate consent forms(s).  Patients have full rights 
to withdraw from the clinical study at any time, irrespectiv e of their initial consent.  
14.2.2.  Each Subject must also give their permission for representatives of the Sponsor, auditor and 
regulatory authorities to review their hospi[INVESTIGATOR_1248].  
14.2.3.  Written informed consent from the Subject must be obtained before any clinical 
investigation related procedures are performed.  
14.3. Subject Confidentiality  
14.3.1.  Confidentiality of Subject data will be maintained at all times.  Subject anonymity will be 
guaranteed a nd all documentation relating to a Subject will be kept in a secure location.  
14.3.2.  Study  documents  provided  to the  Sponsor will be stored  in a secure  location  with access.  
None  of the stored  documents  will contain  any personal  identifying  information  or direct  
identifiers. 
14.3.3.  Study  files will be made  available  to the IRB,  regulatory  authorities,  Sponsor  (or 
designee)  and/or  clinical  study  staff should  they request  access  for auditing  purposes.   
15. Data Management  
  
BioTeke_Home Use_Clinical Performance Study_V2.0_5 May 2022.docx  Page [ADDRESS_615261] 2 years  after the latter  of the 
following  two dates:  the date on which  the study  is terminated  or completed, or the date the declaration of 
emergency is rescinded. In all cases, the Principal Investigator [INVESTIGATOR_479310].  
16. Study Materials   
‚Ä¢ Bio-Self COVID -[ADDRESS_615262]   
‚Ä¢ Bio-Self COVID -[ADDRESS_615263]  Quick Reference Instructions  
‚Ä¢ BioTeke  Website  
17. Literature References  
1. Template for Developers of Molecular and Antigen Diagnostic COVID -[ADDRESS_615264] for Home Use. Version 
November 9, 2021  
2. Template for Developers  of Antigen Tests. Version October 6, 2021  
3. Supplemental Template for Developers of Molecular and Antigen Diagnostic COVID -19 Tests for Screening 
with Serial Testing. Version October 25, 2021  
18. Protocol Amendment History  
Version  Date  Section  Description of Change  Rationale  
1.0 24 Mar 2022   Initial release   
2.0 05 May 2022  5. Synopsis; 
Study Design  Original: The order of testing will be 1) 
Subject self -collection, 2) standard of care 
(SOC) collection by a healthcare practitioner, 
and 3) compa rator test collection by [CONTACT_479315].  
 
Revised to: The order of testing will be 1) 
standard of care (SOC) collection by a 
healthcare practitioner, 2) layperson conducts 
the test on themselves or another study 
participant using the Bio -Self Test, and 3) 
comparator test collection by [CONTACT_479323].  
 Additional input 
from FDA  
2.0 05 May 2022  5. Synopsis; 
Target 
Population  Original: Subjects will be consecutively 
enrolled (i.e., in an ‚Äúall comers‚Äù style) until at 
least [ADDRESS_615265] completed the study.  
Revised to: The first 50 subjects will be 
consecuti vely enrolled (i.e., in an ‚Äúall comers‚Äù 
style) including those who are either 
asymptomatic or symptomatic for COVID -19. Clarification  
  
BioTeke_Home Use_Clinical Performance Study_V2.0_5 May 2022.docx  Page [ADDRESS_615266] been collected from 
asymptomatic su bjects.  
2.0 05 May 2022  5. Synopsis; 
Target 
Population  Clarified  enrollment population : 
At least 30 RT -PCR confirmed positive 
specimens collected from subjects that are 
symptomatic for COVID -19. 
 clarification  
2.0 05 May 2022  5. Synopsis; 
Target 
Population  Original: Up to 600 subjects may be enrolled 
in this study to obtain a minimum of 30 RT -
PCR confirmed positive subjects of which 10 
subjects are asymptomatic and 10 -20% are 
low positive.  
 
Revised to: Up to [ADDRESS_615267] 10 -20% being low positive.  Clari fication  
2.0 05 May 2022  5. Synopsis; 
Site 
Requirements  Revised the minimum of 3 testing locations to 
minimum of 2 testing locations  Administrative  
2.0 05 May 2022  6.8 Study 
Design  Revised the order of sample collection and 
added:   To mitigate any poten tial bias which 
may affect the subject‚Äôs visual interpretation 
of the Bio -Self COVID -[ADDRESS_615268].   Additional input 
from FDA ; 
clarification  
2.[ADDRESS_615269] . Additional input 
from FDA ;  
clarification  
2.0 05 May 2022  Section 7.1.6  Revised enrollment from all comers to:  
The first 50 subjects should be consecutively 
enrolled (i.e., in ‚Äúall comers‚Äù style), including 
those who are either asymptomatic or 
symptomatic for COVID -19.  Following the 
enrollment of the first [ADDRESS_615270] been collected from asymptomatic 
subjects.    
2.0 05 May 2022  Section 7.1.7  Added: Sym ptomatic to the 30 positive 
samples  Administrative  
2.0 05 May 2022  Section 8.3  Revised the order of sample collection  Additional input 
from FDA  
 